ERBB2 and breast cancer: It was recently demonstrated that treatment of ErbB2 positive SKBR3 and BT474 breast cancer cell lines with proteasome inhibitor causes a 50% downregulation of ErbB2 protein expression ([21] and Supplementary Figure 2), indicating that ErbB2 degradation is proteasome independent.